Pre-ablation stimulated thyroglobulin to TSH ratio as a strong predictor of non-generally satisfactory response to initial radioiodine therapy in papillary thyroid carcinoma patients undergoing lateral neck dissection.
OpenAlex 토픽 ·
Thyroid Cancer Diagnosis and Treatment
Thyroid and Parathyroid Surgery
Thyroid Disorders and Treatments
[BACKGROUND] The initial response to radioiodine (³I) therapy is a critical determinant of prognosis in papillary thyroid carcinoma (PTC) patients undergoing therapeutic lateral neck dissection (LND).
- 95% CI 1.328-601.75
- OR 8.939
- Sensitivity 91.4%
- Specificity 90.9%
APA
Weijian Li, Pengpeng Chang, et al. (2026). Pre-ablation stimulated thyroglobulin to TSH ratio as a strong predictor of non-generally satisfactory response to initial radioiodine therapy in papillary thyroid carcinoma patients undergoing lateral neck dissection.. Annals of medicine, 58(1), 2620341. https://doi.org/10.1080/07853890.2026.2620341
MLA
Weijian Li, et al.. "Pre-ablation stimulated thyroglobulin to TSH ratio as a strong predictor of non-generally satisfactory response to initial radioiodine therapy in papillary thyroid carcinoma patients undergoing lateral neck dissection.." Annals of medicine, vol. 58, no. 1, 2026, pp. 2620341.
PMID
41601151
Abstract
[BACKGROUND] The initial response to radioiodine (³I) therapy is a critical determinant of prognosis in papillary thyroid carcinoma (PTC) patients undergoing therapeutic lateral neck dissection (LND). This study aimed to identify predictors of non-generally satisfactory response (n-GR), defined as biochemical incomplete response or structural incomplete response, following initial ¹³¹I therapy.
[METHODS] We retrospectively analyzed 145 PTC patients who underwent therapeutic LND and initial ¹³¹I therapy. Clinicopathological characteristics, preablation stimulated thyroglobulin (Pre-sTg), thyroid-stimulating hormone (TSH) levels, and lymph node metastasis parameters were evaluated. Multivariate logistic regression and receiver operating characteristic (ROC) curve analyses identified predictors of n-GR at 6 months post-therapy.
[RESULTS] n-GR was observed in 24.2% (35/145) of patients. Multivariate analysis identified lateral neck metastasis burden (Odds Ratio [OR]: 1.026 per 1% increase, 95% Confidence Interval [CI]: 1.001-1.052, = 0.040) and the Pre-sTg/TSH ratio (OR: 8.939 per 0.1 increase, 95%CI: 1.328-601.75, = 0.041) as independent predictors of n-GR. The Pre-sTg/TSH ratio exhibited outstanding predictive performance (AUC = 0.955) with an optimal cutoff value of 0.127 (sensitivity: 91.4%, specificity: 90.9%). Integration of a Pre-sTg/TSH ratio > 0.127 into ATA recurrence risk categories significantly improved n-GR risk stratification: among intermediate-risk patients, the n-GR rate increased from 14.5% to 68.2%, and among high-risk patients, from 60.0% to 85.0%.
[CONCLUSION] In our pilot study a Pre-sTg/TSH ratio > 0.127 significantly enhances risk stratification in PTC patients undergoing therapeutic LND when combined with ATA recurrence risk categories, supporting its potential use in personalizing treatment and follow-up strategies. Further validation in larger, multi-center cohorts is warranted.
[METHODS] We retrospectively analyzed 145 PTC patients who underwent therapeutic LND and initial ¹³¹I therapy. Clinicopathological characteristics, preablation stimulated thyroglobulin (Pre-sTg), thyroid-stimulating hormone (TSH) levels, and lymph node metastasis parameters were evaluated. Multivariate logistic regression and receiver operating characteristic (ROC) curve analyses identified predictors of n-GR at 6 months post-therapy.
[RESULTS] n-GR was observed in 24.2% (35/145) of patients. Multivariate analysis identified lateral neck metastasis burden (Odds Ratio [OR]: 1.026 per 1% increase, 95% Confidence Interval [CI]: 1.001-1.052, = 0.040) and the Pre-sTg/TSH ratio (OR: 8.939 per 0.1 increase, 95%CI: 1.328-601.75, = 0.041) as independent predictors of n-GR. The Pre-sTg/TSH ratio exhibited outstanding predictive performance (AUC = 0.955) with an optimal cutoff value of 0.127 (sensitivity: 91.4%, specificity: 90.9%). Integration of a Pre-sTg/TSH ratio > 0.127 into ATA recurrence risk categories significantly improved n-GR risk stratification: among intermediate-risk patients, the n-GR rate increased from 14.5% to 68.2%, and among high-risk patients, from 60.0% to 85.0%.
[CONCLUSION] In our pilot study a Pre-sTg/TSH ratio > 0.127 significantly enhances risk stratification in PTC patients undergoing therapeutic LND when combined with ATA recurrence risk categories, supporting its potential use in personalizing treatment and follow-up strategies. Further validation in larger, multi-center cohorts is warranted.
MeSH Terms
Humans; Male; Female; Thyroid Neoplasms; Iodine Radioisotopes; Middle Aged; Thyroglobulin; Retrospective Studies; Neck Dissection; Adult; Thyroid Cancer, Papillary; Thyrotropin; Carcinoma, Papillary; Lymphatic Metastasis; Aged; Carcinoma; Treatment Outcome; Prognosis; ROC Curve
같은 제1저자의 인용 많은 논문 (5)
- Exploring the Potential of ChatGPT-4 in Responding to Common Questions About Abdominoplasty: An AI-Based Case Study of a Plastic Surgery Consultation.
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- ESPNP promotes cell migration and invasion in gastric cancer cells via regulation of epithelial-mesenchymal transition/Twist1.
- Integration of a glutamine metabolism-based prognostic signature and a synergistic nanotherapeutic strategy targeting metabolic vulnerabilities in prostate cancer.
- Multiparametric MRI-based longitudinal-radiomics analysis for early prediction of treatment response of breast cancers to neoadjuvant chemotherapy.